Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ERSP on CigArrest

This article was originally published in The Tan Sheet

Executive Summary

CigArrest, marketer of the eponymous smoking cessation program, has adequately supported its general performance and safety claims, but should modify or discontinue its claim that users can "become a non-smoker in as little as seven days," according to an Electronic Retailing Self-Regulation Program decision Feb. 24. ERSP reviewed a TV ad and website promoting the product and expressed concern about claims such as: "clinically proven methods to help you avoid smoking in any situation" and "the most successful stop smoking program." However, the National Advertising Review Council division found that ingredient claims such as "the active ingredients relieving nervous tension, irritability and the craving associated with withdrawal" were given "adequate" support by scientific literature. Additionally, safety claims including "all-natural, non-addictive" and "we have not had any serious reactions or adverse side-effects ever reported" were reasonably supported by the marketer, ERSP states. CigArrest is a homeopathic formula that includes Nux Vomica (poison nut) and Plantago Major (plantain), the marketer states...

You may also be interested in...

ERSP Review Of Claims Lights Fire Under Smoking-Cessation Marketer

Final Smoke Inc. voluntarily modifies claims for its smoking-cessation system, including a dietary supplement and homeopathic detoxification liquid, in conjunction with an Electronic Retailing Self-Regulation Program review

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts